All rights reserved. No reuse allowed without permission.

### Article

# An Optimised Monophasic Faecal Extraction Method for LC-MS Analysis and its Application in Gastrointestinal Disease

Patricia E. Kelly <sup>1,5</sup>, H Jene Ng<sup>2</sup>, Gillian Farrell<sup>1</sup>, Shona McKirdy<sup>2,5</sup>, Richard K. Russell<sup>3,5</sup>, Richard Hansen<sup>4,5</sup>, Zahra Rattray<sup>1</sup>, Konstantinos Gerasimidis<sup>2,5</sup>, Nicholas J.W. Rattray<sup>1,5</sup> \*

- <sup>1</sup> Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow, United Kingdom
- <sup>2</sup> School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow Royal Infirmary, United Kingdom, G31 2ER
- <sup>3</sup> Royal Hospital for Children and Young People, 50 Little France Crescent, Edinburgh EH16 4TJ
- <sup>4</sup> Royal Hospital for Children, 1345 Govan Road, Glasgow G52 4TF
- <sup>5</sup>Bacteria, Immunology, Nutrition, Gastroenterology and Omics Group, University of Glasgow; Glasgow, UK \*Correspondence: <u>nicholas.rattray@strath.ac.uk</u>

Abstract: Liquid chromatography coupled with mass spectrometry (LC-MS) metabolomic ap-15 proaches are widely used to investigate underlying pathogenesis of gastrointestinal disease and 16 mechanism of action of treatments. However, a standardised method for extracting metabolites 17 from faecal samples for large-scale metabolomic studies is yet to be defined. Current methods often 18 rely on biphasic extractions using harmful halogenated solvents, making automation and large-19 scale studies challenging. The present study reports an optimised monophasic faecal extraction pro-20 tocol that is suitable for untargeted and targeted LC-MS analyses. The impact of several experi-21 mental parameters, including sample weight, extraction solvent, cellular disruption method, and 22 sample-to-solvent ratio were investigated. It is suggested that a 50 mg freeze-dried faecal sample 23 should be used in a methanol extraction (1:20) using bead beating as the means of cell disruption. 24 This is revealed by a significant increase in number of metabolites detected, improved signal inten-25 sity, and wide metabolic coverage given by each of the above extraction parameters. Finally, we 26 addressed the applicability of the method on faecal samples from patients with Crohn's disease 27 (CD) and coeliac disease (CoD), two distinct chronic gastrointestinal diseases involving metabolic 28 perturbations. Untargeted and targeted metabolomic analysis demonstrated the ability of the de-29 veloped method to detect and stratify metabolites extracted from patient groups and healthy con-30 trols (HC), highlighting characteristic changes in the faecal metabolome according to disease. The 31 method developed is therefore suitable for the analysis of patients with gastrointestinal disease and 32 can be used to detect and distinguish differences in the metabolomes of CD, CoD, and HC. 33

34

1

2

3

4

5

6

7

8 9

10

11

12

13 14

35

36

37 38

**Keywords:** mass spectrometry; metabolite extraction; inflammatory bowel disease; Crohn's disease; coeliac disease

39

40

#### 1. Introduction

Metabolomics is a powerful tool for detecting small molecule cellular and microbial 41 products. Through the reflection of active physiological mechanisms, metabolite charac-NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 42 terisation and quantification can give critical insights into human health and disease. The large abundance and diversity of metabolites that are present in human faecal samples, as 44

All rights reserved. No reuse allowed without permission.

given by the identification of over 6700 faecal metabolites on the Human Metabolome 45 Database (HMBD - <u>https://hmdb.ca/</u>) [1], provides an ideal target for metabolomic analy-46 sis [2] and thus allows insights into outcomes of gut-microbial interactions and dietary 47 impacts on disease [3]. Accumulating evidence indicating the involvement of the gut 48metabolome in a multitude of diseases [4-6] has propelled an intense interest in the role 49 of faecal metabolites under certain environments. The accurate quantification of metabo-50 lites in faecal samples therefore holds value in a wide range of research areas. A clear role 51 of faecal metabolomics has been demonstrated in the field of gastrointestinal disease, in-52 cluding inflammatory bowel disease (IBD) [7] and coeliac disease (CoD) [8]. Although the 53 aetiology of such diseases remains elusive, shifts in metabolic profile are associated with 54 disease activity and may represent central components of pathogenesis [9-12]. Irrespec-55 tive, detection of altered patient metabolites may help unravel underlying disease mech-56 anisms or reveal new diagnostic or prognostic markers of clinical utility. .57

58

89

Liquid-chromatography mass spectrometry (LC-MS) is a popular metabolite analysis 59 technique due to its high sensitivity and selectivity. Sample preparation and pre-treatment 60 is a vital stage of the LC-MS workflow, providing the scaffolding to support metabolite 61 detection. The experimental framework therefore shapes the biological interpretation of a 62 metabolomics study and so it is crucial to consider best practices regarding specific study 63 aims. Certain challenges are inherent in the sample preparation phase, such as the large 64 physio-chemical variation of the target metabolite pool, technical and environmental var-65 iation, and the complex and heterogeneous nature of human faeces. This brings difficul-66 ties in standardizing metabolomic methods, which is evident in the lack of "gold stand-67 ard" metabolite extraction procedures. As the effective and reliable identification of me-68 tabolites is largely dependent on the extraction method used, it is imperative to consider 69 sample preparation when comparing results between studies. To date, previous studies 70 have addressed some of the challenges associated with metabolomic sample preparation 71 [13-15], however these are mainly based on biphasic extraction protocols with limitations 72 in scalability: While efficient biphasic extraction systems for faecal analysis contribute to-73 wards protocol standardisation, they are associated with complicated handling due to the 74 requirement for phase separation. It can therefore be challenging to utilise two-phase pro-75 tocols in large scale clinical studies, with further limitations in protocol automation. With 76 the increasing demand for translating metabolomics data into meaningful clinical output, 77 one major requirement for bridging the bench to bedside gap is the use of large population 78 studies. It is therefore also important to optimise less-complex monophasic extraction pro-79 tocols that can be used as an alternative to classical biphasic protocols for LC-MS analysis. 80 Moreover, the applicability of metabolite extraction in the context of gastrointestinal dis-81 ease requires further acknowledgement. Thus, the present study has the goal of advancing 82 a method for monophasic metabolite extraction that can be easily implemented in large 83 scale clinical studies investigating gastrointestinal disease. To the best of our knowledge, 84 there is no current documentation on optimal extraction methods for IBD or CoD samples 85 for LC-MS analysis. There is an important unmet requirement for the effect of faecal sam-86 ple type to be explored, which is exemplified here in the comparison between gastrointes-87 tinal disease and the non-disease state. 88

Herein, we evaluate different faecal extraction methods for metabolomic measure-90 ments in human faecal samples from healthy individuals, Crohn's Disease (CD) and CoD 91 patients. A range of trial experiments were performed to determine the optimal sample 92 weight, extraction solvent, disruption method, and sample-to-solvent ratio using LC-MS. 93 The overall aim of this study is twofold; firstly, to optimise metabolite extraction param-94 eters for faecal samples and secondly, to determine whether this optimised extraction pro-95 tocol is suitable for analysis of samples from patients with gastrointestinal disease. To 96 capture the large quantity of metabolites and ensure maximal coverage in the method 97 development phase, untargeted metabolomic analysis was performed to assess each 98

All rights reserved. No reuse allowed without permission.

sample parameter. Targeted metabolomic analysis was subsequently applied to assess 99 method suitability in patients with disease. 100 101 2. Materials and Methods 102 103 2.1 Overall Experimental Workflow 104 The overall experimental workflow including extraction, LC-MS metabolite meas-105 urement, data analysis, and data quantification and interpretation are shown Supplemen-106 tary Information Figure S1). 107 108 2.2 Ethics Statement 109 All participants and their carers provided written informed consent. The study was 110 approved by the NHS West of Scotland Research Ethics Committee (Ref: 11/WS/0006) for 111 the study in patients with coeliac disease and the Yorkhill Research Ethics Committee 112 (Reb: 05/S0708/66) for the study in patients with Crohn's disease. 113 114 2.3 Faecal Samples 115 Faecal samples were collected for metabolomic analysis and freeze-dried prior to 116 processing. Samples were stored at -80 °C until metabolite extraction and again until LC-117 MS analysis. Samples were kept on ice during transportation. 118 119 2.4 Chemicals and Reagents 120 LC-MS grade methanol (MeOH), acetonitrile (ACN), chloroform (CHCl<sub>3</sub>), and water 121 (H<sub>2</sub>O) were purchased from Fisher Scientific (Geel, Belgium). LC-MS grade formic acid 122 was purchased from Thermo Scientific (Czech Republic). 123 124 2.5 Extraction Protocol 125 Freeze-dried faecal sample was added to extraction solvent and cells were disrupted 126 using bead beating (FastPrep 24 MP Biomedicals), sonication, and freeze-thaw lysis meth-127 ods. Samples were then centrifuged at 13,000 g for 15 minutes and the supernatant recov-128 ered. Samples were lyophilised for 36 hours and stored at -80 °C until further processing. 129 Reconstitution was performed in 250  $\mu$ L 50/50 H<sub>2</sub>O: acetonitrile (ACN), vortexed for 1 130 minute and centrifuged at 15,000 g for 15 minutes, and aliquots transferred into glass vials 131 for MS analysis. Quality control (QC) samples were prepared by pooling samples across 132 all groups undergoing simultaneous analysis. Solvent blanks and QC samples were en-133 tered at the beginning of every analytical run and after every five samples in each batch 134 over the course of the study to assess background in the system and detect potential con-135 taminations. 136 137 Table 1. Details of experimental conditions for each extraction parameter. 138

Experiment	Independent variable	Sample weight	Solvent used	Cell lysis method
1	Sample weight	10 mg, 20 mg, 50 mg, 100 mg	MeOH	Bead beating (5 ms-1, 60s)
2	Extraction solvent	50 mg	MeOH, MeOH/H2O,	Bead beating (5 ms <sup>-1</sup> ,
			CHCl <sub>3</sub> / MeOH	60s)
3	Cell lysis method	50 mg	MeOH	Bead beating (5 ms <sup>-1</sup> ,
				60s), sonication (40
				kHz) freeze-thaw cycle
				(24 hours)
4	Sample-to-solvent ratio	50 mg	МаОН	Bead beating (5 ms <sup>-1</sup> ,
		JUIIIg	WIEOT1	60s)

All rights reserved. No reuse allowed without permission.

#### 2.6 Untargeted LC-MS Metabolite Measurement

Untargeted metabolomic analysis was performed on an ultra-high performance liq-141 uid chromatography UHPLC) system (ThermoFisher Scientific) coupled to an Orbitrap 142 Exploris 240 (ThermoFisher Scientific) mass spectrometer. Chromatographic separation 143 was performed on a Vanquish Accucore C18 + UHPLC analytical column (ThermoScien-144 tific, 100 mm x 2.1 mm, 2.6  $\mu$ M) at a flow rate of 400  $\mu$ L min <sup>-1</sup>. Mobile phase A was com-145 posed of 99.9% water + 0.1% formic acid and mobile B was composed of 99.99% MeOH + 1460.1% formic acid. Electrospray ionisation (ESI) was used as the ionisation method, set at 147 3900 V and 2500 V for positive and negative mode, respectively. The elution gradient used 148can be found in Supplementary Information Table S1. The source-dependent parameters 149 were operated under the following conditions: sheath gas, 40 Arb; auxiliary gas, 10 Arb; 150 sweep gas, 1 Arb; ion transfer tube temperature, 300 °C; vaporiser temperature, 280 °C. 151 Instrument calibration was performed using Pierce<sup>TM</sup> FlexMix<sup>TM</sup> calibration solution 152 (Thermo Scientific) and ran under vendor recommended settings. MS data collection was 153 performed in a top-5 data dependent acquisition mode (DDA). 154

#### 2.7 Targeted LC-MS Metabolite Measurement

Targeted metabolomic analysis was performed on an ultra-high-performance liquid 157 chromatography (UHPLC) system coupled to a triple quadrupole mass spectrometer (Shi-158 madzu 8060NX). The method used for metabolite detection and quantification was pro-159 vided by the vendor: Primary Metabolites LC/MS/MS Method Package version 2.0 The 160 method is designed to detect 97 metabolites. The list of 97 detected metabolites is shown 161 in Supplementary Information Table S3. Chromatographic separation was performed on 162 a pentafluorophenylpropyl (PFPP) + UHPLC analytical column (Merck, 150 mm x 2.1 mm, 163  $3 \,\mu\text{M}$ ) at a flow rate of 400  $\mu\text{L}$  min <sup>-1</sup>. Mobile phase A was composed of 99.9% water + 0.1% 164 formic acid and mobile B was composed of 99.9% acetonitrile + 0.1% formic acid. Elec-165 trospray ionisation (ESI) was used as the ionisation method, set at 3900 V and 2500 V for 166 positive and negative mode, respectively. The source-dependent parameters were oper-167 ated under the following conditions: column oven temperature, 40 °C; nebulising gas flow 168 rate, 3.0 L min<sup>-1</sup>, drying gas flow rate, 10 L min<sup>-1</sup>, desolvation line temperature, 250 °C; 169 block heater temperature, 400 °C. The elution gradient used can be found in Supplemen-170 tary Information Table S2. 171

#### 2.8 Method Application

We applied the method to three biological groups: CD patients, CoD patients, and 175 HCs. CD patients were undergoing varying forms of treatment and CoD patients were 176 following a gluten-free diet. HCs were defined as individuals with the absence of gastrointestinal disease. Untargeted and targeted metabolomic analyses were applied to the 178 sample sets combined after randomisation. 179

180 181

172 173

174

**Table 2.** Table of patient demographics. HC, healthy control; CD, Crohn's disease, CoD, Coeliac182disease.183

X7 · 11	HC	CD	CoD
Variable	n=20	n=20	n=20
Gender			
Female (%)	45	40	60
Male (%)	55	60	40
Age (range)	6.6 (2.3-13.7)	12.3 (7.6-14.8)	9.2 (4.0-14.8)
BMI z-score	0.3	- 0.7	0.2

185

186

140 141

155

All rights reserved. No reuse allowed without permission.

For the processing of untargeted metabolomics data, Thermo Scientific Xcalibur format raw data files (.RAW) were imported into Compound Discoverer software (version 188 3.2). Details of the workflow for analysis in Compound Discoverer is included in Supplementary Information Table S4. Targeted metabolomics data were converted from Shimazdu vendor format (.lcd) to mzML format. A data matrix of identified metabolites and associated peak areas was constructed and processed using R-Studio v 3.5.2. 192

193

194

205

206

213

214

220

221

#### 2.10 Data and Statistical Analysis

For untargeted analysis, multivariate statistical analysis was performed using Com-195 pound Discoverer software 3.2. For targeted analysis, multivariate statistical analyses 196 were performed using Lab Profiling Solutions software version 1.1 and R-Studio. Princi-197 pal component analysis (PCA) was used to reduce data dimensionality, through which 198 PCs were calculated using prcomp function and PCA scores plots were generated using 199 the following packages in R: ggplot2, ggfortify, grid, and gridExtra. Differential analysis 200 using volcano plots allowed significant differences between groups to be determined. 201 Univariate statistical analyses were performed using unpaired t-test and one-way 202 ANOVA, with the level of significance set at p < 0.05. Central network analysis was per-203 formed in R-studio using the igraph package. 204

#### 2.11 Metabolite Identification

Inclusion criteria for metabolite identification were set and applied to refine the total 207 number of features (Supplementary Information Figure S2). The resulting list contained 208 only metabolites within a 10 ppm mass accuracy range and with a full predicted composition and ChemSpider match. Contaminations were excluded by analysing 50:50 210 H<sub>2</sub>O/MeOH blank samples throughout the MS run. Metabolite annotation was performed 211 manually and using the HMDB. 212

#### 3. Results

For method development, metabolites were measured in freeze-dried faecal samples 215 obtained from healthy participants. The metabolic output was first measured by PCA to 216 observe any differences in the overall metabolic signature obtained from each method. 217 Further statistical analysis was performed for data quantification by calculating the number of m/z features, identified metabolites, signal intensity, and metabolic coverage. 219

#### 3.1. Analysis of Sample Weight

A significantly higher number of m/z features were detected through the positive 222 ionisation acquisition mode in comparison to the negative ionisation mode (Supplemen-223 tary Information Figure S3). For this reason, the positive ionisation mode was subse-224 quently used for further analysis of experimental parameters. Metabolite extraction from 225 10 mg and 100 mg samples were unsuitable for metabolomic analysis and therefore not 226 included in the results. Metabolites were successfully extracted from 20 mg and 50 mg 227 samples and measured using LC-MS. Multivariate statistical analysis demonstrated clear 228 separation of the two sample weight groups (Fig. 1). 50 mg samples showed a significantly 229 higher mean number of m/z features and mean number of identified metabolites in com-230 parison to 20 mg samples. Furthermore, the mean signal intensity given by 50 mg samples 231  $(2.5 \times 10^7)$  was significantly increased compared to 20 mg samples  $(1.1 \times 10^7)$ . Levels of al-232 tered metabolites were calculated from the differential analysis of sample weight and ex-233 pressed as the percentage of significantly increased metabolites between groups. It was 234 demonstrated that 59.6% of identified metabolites were found at significantly increased 235 levels in 50 mg samples compared to 20 mg samples (Supplementary Information Figure 236 S4). All metabolite classes were detected from both sample groups, with similar composi-237 tions of chemical class observed. A comparison of the total number of metabolites per 238

All rights reserved. No reuse allowed without permission.





Figure 1. Effect of sample weight on features of metabolomic analysis. 1 µL of 20 mg and 50 mg 262 sample was injected onto a C18 column (n=3), performed in triplicate. (a) Multivariate analysis of 263 metabolomic profiles obtained as a function of sample weight. PCA score plots demonstrating ex-264 tracted faecal metabolites between different sample weights. Discrimination between 20 mg (blue) 265 and 50 mg (orange) samples was characterised by a variability of 71.6%. (b) Venn diagram of the 266 mean number of identified metabolites between each method. (c) The total number of m/z features 267 and (d) total number of identified metabolites were calculated in positive ionisation mode and (e) 268 the overall mean signal intensity of each sample weight was assessed. (f) Metabolite class quantifi-269 cation demonstrating the faecal metabolome patterns identified by chemical class in 20 mg and 50 270 mg samples. Bar chart data are expressed as mean ± SEM and statistical significance was assessed 271 using an unpaired t-test. \*p < 0.05, \*\*\*\* p < 0.0001. 272

273

274

All rights reserved. No reuse allowed without permission.

Multivariate statistical analysis demonstrated clear separation of the extraction solvents (Fig. 2). Using 100% MeOH gave a significantly higher number of m/z features in compar-ison to MeOH/H2O and a significantly higher number of identified metabolites than both MeOH/ H2O and CHCl<sub>3</sub>/ MeOH. No significant differences were observed in the signal intensity between the extraction solvents. Differential analysis revealed a significant in-crease in the levels of 28.5% and 9.3% of identified metabolites using MeOH as the extrac-tion solvent in comparison to MeOH/ H2O and CHCl3/ MeOH, respectively (Supplemen-tary Information Figure S6). 25.8% of identified metabolites were found at significantly increased levels in CHCl<sub>3</sub>/ MeOH compared to MeOH/ H2O. MeOH extractions addition-ally had a significantly increased number of lipids compared to MeOH/ H2O extractions. Again, all metabolite classes were detected from all extraction solvents, with a similar structure of metabolite classification. A comparison of the total number of metabolites per chemical class identified using each extraction solvent is shown in Supplementary Infor-mation Figure S7. 

All rights reserved. No reuse allowed without permission.



318

Figure 2. Effect of extraction solvents, MeOH, MeOH/H2O, and CHCl3/ MeOH, on features of metab-319 olomic analysis. 1 µL of each extraction sample was injected onto a C18 column (n=3), performed in 320 triplicate. (a) Multivariate analysis of metabolomic profiles obtained as a function of extraction sol-321 vent. PCA score plots demonstrating extracted faecal metabolites between different extraction sol-322 vents. Discrimination between extraction solvents MeOH (light blue), MeOH/H2O (orange), and 323 CHCl<sub>3</sub>/MeOH (dark blue) was characterised by a variability of 40.2%. (b) Venn diagram of the mean 324 number of identified metabolites between each method. (c) The total number of m/z features and 325 (d) total number of identified metabolites were calculated in positive ionisation mode and (e) the 326 overall mean signal intensity of each extraction solvent was assessed. (f) Metabolite class quantifi-327 cation demonstrating the faecal metabolome patterns identified by chemical class in each extraction 328 sample. Bar chart data were expressed as mean ± SEM and statistical significance was assessed using 329 one-way ANOVA. \*p < 0.05, \*\* p < 0.01. 330

All rights reserved. No reuse allowed without permission.

## 

### 3.3. Analysis of the Cellular Disruption Method

The choice of cellular disruption method affected the overall metabolic output, as shown by multivariate statistical analysis which demonstrated clear separation between the three groups (Fig.3). Bead beating extracted a significantly higher mean number of m/z features in comparison to freeze-thawing and a significantly higher number of identified metabo-lites than both sonication and freeze-thawing. No significant differences were observed in the signal intensity between lysis methods. A significant increase in the levels of 32.9% and 48.6% of identified metabolites were found using bead beating as the method of cel-lular disruption compared to sonication and freeze-thawing, respectively (Supplementary Information Figure S8). Of the metabolites identified, 26.2% were found at significantly increased levels in sonicated samples in comparison to freeze-thawing. Each disruption method allowed measurement of metabolites from all classification groups. While similar patterns of metabolite classification are shown between methods, it was shown that bead beating led to detection of a significantly increased number of lipids compared to the other lysis techniques. A comparison of the total number of metabolites per chemical class iden-tified using each cellular disruption method is shown in Supplementary Information Fig-ure S9. 

All rights reserved. No reuse allowed without permission.



371

Figure 3. Effect of cellular disruption methods, bead beating, sonication, and freeze-thaw cycles, on 372 features of metabolomic analysis. 1 µL of each extraction sample was injected onto a C18 column 373 (n=3), performed in triplicate. (a) Multivariate analysis of metabolomic profiles obtained as a func-374 tion of disruption method. PCA score plots demonstrating extracted faecal metabolites between 375 bead beating, sonication, and freeze-thaw cycles. Discrimination between extraction solvents A, 376 bead beating (dark blue); B, sonication (orange) and C, freeze-thaw cycles (light blue) was charac-377 terised by a variability of 33.5%. (b) Venn diagram of the mean number of identified metabolites 378 between each method. (c) The total number of m/z features and (d) total number of identified me-379 tabolites were calculated in positive ionisation mode and (e) the overall mean signal intensity of 380 each disruption method was assessed. (f) Metabolite class quantification demonstrating the faecal 381 metabolome patterns identified by chemical class in each extraction sample. Bar chart data were 382 expressed as mean ± SEM and statistical significance was assessed using a one-way ANOVA. \*p < 383 0.05, \*\*\*\* p < 0.0001. 384

All rights reserved. No reuse allowed without permission.

#### 3.4. Analysis of Sample-to Solvent Ratio

Clear separation was observed between the three different sample-solvent ratios by PCA 387 (Fig.4). Performing extractions using a ratio of 1:20 gave a significantly higher mean num-388 ber of m/z features and identified metabolites than ratios of 1:5 and 1:10. Furthermore, a 389 significant increase in the signal intensity of samples of a 1:20 ratio was observed in com-390 parison to the other groups. A significant increase in the levels of 70.2% and 67.3% of 391 identified metabolites were found using a ratio of 1:20 in comparison to ratios of 1:5 and 392 1:10, respectively (Supplementary Information Figure S10). 70.2% of identified metabo-393 lites were found at significantly increased levels in samples extracted using a ratio of 1:10 394 compared to 1:5. Amino acids and derivatives, lipids and derivates, organooxygen, and 395 organoheterocyclic compounds were significantly increased in extractions carried out us-396 ing a ratio of 1:20 compared to the other groups. Additionally, the overall composition 397 according to chemical class of each sample remained similar between each group. A com-398 parison of the total number of metabolites per chemical class identified using each sample-399 to-solvent ratio is shown in Supplementary Information Figure S11. 400

Through exploration of the overall metabolite extraction efficiency through the optimisa-401tion process, it was observed that both the number of m/z features and identified metab-402olites significantly increased throughout stages of method optimisation with the improve-403ment of each individual extraction parameter (Supplementary Information Figure S12).404

405

385

386

406

407

- 408
- 409
- 410

411

412

413

All rights reserved. No reuse allowed without permission.



Figure 4. Effect of sample-solvent ratio on features of metabolomic analysis. 1 µL of each extraction 430 sample was injected onto a C18 column (n=3), performed in triplicate. (a) Multivariate analysis of 431 metabolomic profiles obtained as a function of sample-to-solvent ratio. PCA score plots demonstrat-432 ing extracted faecal metabolites between different ratios. Discrimination between extraction sol-433 vents 1:5 (dark blue), 1:10 (orange) and 1:20 (light blue) was characterised by a variability of 33.3%. 434 (b) Venn diagram of the mean number of identified metabolites between each method. (c) The total 435 number of m/z features and (d) total number of identified metabolites were calculated in positive 436 ionisation mode and (e) the overall mean signal intensity of each sample-to-solvent-ratio was as-437 sessed. (f) Metabolite class quantification demonstrating the faecal metabolome patterns identified 438 by chemical class in each extraction sample. Bar chart data are expressed as mean ± SEM and statis-439 tical significance was assessed using a one-way ANOVA. \*\*p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001. 440

441

442

443

All rights reserved. No reuse allowed without permission.

To assess the applicability of the developed method, we applied the protocol to CD, CoD, 445 and HC groups and compared the metabolic differences. In an untargeted analysis, mul-446 tivariate statistics demonstrated clear separation between CD samples and the other 447 groups (Fig.5). A significant decrease in the levels of 72.3% of identified metabolites were 448 found in CD samples compared to HCs, and 74.1% compared to CoD samples (Supple-449 mentary Information Figure S13). Of the metabolites identified, 27.1% were found at sig-450nificantly decreased levels in CoD samples in comparison to HCs. Furthermore, targeted 451 metabolomics analysis further confirmed the ability of the method to both detect and strat-452 ify metabolites extracted from faecal sample from patients with CD and CoD and healthy 453 individuals. Multivariate analysis showed characteristic changes in the faecal metabolome 454 between each of the groups (Fig.6). 455



Figure 5. Multivariate analysis of metabolomic profiles based on untargeted analysis of gastrointes-457 tinal disease. PCA score plots demonstrating extracted faecal metabolites between patient groups. 458 Principle Component 1 directionality describes the variance between CD (dark blue), CoD (orange) 459 and HC (light blue) and explains 17.7% of the total variance of the data. QCs are shown in green. Samples are represented by individual datapoints, performed in triplicate (n=20). 461

460

456

All rights reserved. No reuse allowed without permission.



Figure 6. Multivariate analysis of the metabolomic profiles based on targeted analysis of gastroin-<br/>testinal disease. PCA score plots demonstrating extracted faecal metabolites between CD (dark<br/>blue), CoD (orange) and HC (light blue). Discrimination between (a) CD vs. HC, (b) CoD vs. HC,<br/>and (c) CD vs. Co was characterised by variabilities of 34.5%, 31.3%, and 10.5%, respectively. Samples are represented by individual datapoints, performed in triplicate (n=20).465469

470

464

To ensure the present method was effective in the specific context of gastrointestinal dis-471 ease, we carried out further analysis investigating metabolites that are important in IBD. 472 Metabolites previously implicated in IBD pathology throughout the literature were iden-473 tified, through a significant alteration of their levels in individuals with disease in com-474 parison to healthy controls. A cross-study analysis was then carried out to assess whether 475 the method developed in the present study was able to successfully detect those metabo-476 lites identified with involvement in IBD. It was found that the present method detected 477 75% of the metabolites identified in the IBD target list (Fig.7). 478

All rights reserved. No reuse allowed without permission.



Figure 7. Central network analysis of developed metabolite extraction method. Circles shown in481green represent metabolites successfully extracted using the developed method and circles shown482in red represent metabolites not found using the developed method. C1P, Ceramide-1-phosphate;483AA, Arachidonic acid; EPA, Eicosapentanenoic acid; DGLA, Dihomo-gamma linolenic acid.484

485

486 487

4. Discussion

Since extraction methodology directly affects metabolite constitution within MS 488 metabolomics experiments, it was important to optimise a range of experimental param-489 eters and document the chemical coverage in faecal samples. To this end, the present 490 study first aimed to assess parameters of maximal metabolic LC-MS output, utilising an 491 untargeted metabolomics approach to allow fingerprinting of the total metabolite profile 492 in samples. The ideal extraction protocol was therefore one that elucidated the greatest 493 number of metabolites whilst minimizing interferences. As such, methods were evaluated 494 by measuring the total number of metabolites detected using each protocol. Since we can-495 not assume that the number of features is equal to the number of correctly identified me-496 tabolites, due to unmatched features, blanks, and duplicate readings, further refinement 497 methods were applied to allow for a more accurate evaluation of the protocols. Addition-498 ally, the markedly different characteristics of metabolites in the faecal metabolite pool 499 brings challenges in extracting all the metabolites present in each sample. For this reason, 500 it was important to assess the number of metabolites belonging to different metabolic 501

All rights reserved. No reuse allowed without permission.

classes from each method to ensure maximum chemical coverage. Feature annotation was 502 performed to quantify and compare metabolite classifications between the extraction 503 methods. As complete characterisation of the metabolome is not possible, a compromise 504 will always exist in practice, however the multi-parameter method used in the present 505 study allows method selection of the greatest coverage largely without sacrificing data 506 quality. 507

Herein, we describe an optimised protocol for extraction of metabolites from human 509 faecal samples, thus providing an efficient setup for subsequent metabolomic analysis. 510 The method is recapitulated in the following stages: (1) 50 mg sample weighed out; (2) 511 1000 µL MeOH added to sample and cell lysed by bead beating; (3) samples lyophilised 512 and stored at -80 °C until further processing; (4) reconstitution carried out in 50/50 ACN: 513 H<sub>2</sub>O; (5) LC-MS analysis using 1 µL injection volume (Fig.8). 514



Figure 8. Summary of the developed methodology pipeline. Multi-parameter analysis showed that 517 50 mg samples give the strongest MS output, and from the extraction solvents analysed, MeOH is 518 the most effective. Additionally, cellular metabolite release is optimal using bead beating as the cell 519 lysis method. Combining optimised parameters provides an experimental protocol for faecal me-520 tabolite extraction that can be used for metabolomic analysis. 521

While examining the effect of sample weight, 10 mg samples were disregarded dur-523 ing the extraction process as the aliquots had very little extractable supernatant for subse-524 quent processing. This was likely due to the sample being absorbed by the zirconium 525 beads as the sample weight was too small for the solvent volume. During the reconstitu-526 tion step, the 100 mg sample was also disregarded as there was too much particulate left 527 undissolved. This is important as when run on the MS, sample particulate may crash the 528 column and lead to instrument damage. The faeces weight-to-solvent ratio (100 µL of sol-529 vent for every 10 mg of sample) was therefore not sufficient for samples out with a 20-50 530 mg range. For this reason, we explored the impact of sample-solvent ratio on metabolic 531 output in a further analysis (experiment 4). In consideration to this, for the assessment of 532 sample weight, 20 mg and 50 mg samples were successfully extracted and metabolomic 533 analysis was continued. 534

A clear separation was shown by the PCA comparing 20 mg and 50 mg samples, 536 indicating the different metabolite profiles given by the two groups. Further analysis 537 showed that 50 mg samples additionally contained an increased number of m/z features, 538 identified metabolites, and signal intensity – this result was to be expected due to the in-539 creased levels of biomass in the 50 mg samples. It was also important to investigate 540 whether the observed differences in metabolite numbers were reflected in the overall met-541 abolic coverage. Thus, the identified metabolites were grouped according to their chemi-542 cal classification, and calculation of the number of metabolites in each class was used as a 543 measurement of metabolic coverage. This is essential for untargeted metabolomics exper-544 iments, as the analytical conditions should aim to detect a broad range of metabolites of 545 different chemical properties that may be implicated in disease. As such, expansion of 546

516

522

535

All rights reserved. No reuse allowed without permission.

metabolic coverage is important to maximise information for hypothesis generation. From
the classification analysis, it was revealed that metabolite class is conserved across sample
weight. Using 50 mg faecal samples for metabolite extraction aligns with previously reported studies [3, 16-18], in which 50 mg samples were also used as the starting point for
sample preparation and subsequent analysis. Based on findings of increased metabolite
suggest that 50 mg samples are optimal for use in faecal extraction protocols.

554

574

590

Analysis of extraction solvent also showed a clear separation between protocols us-555 ing MeOH, MeOH, MeOH/H2O, and CHCl3/ MeOH, with an increased number of m/z 556 features and identified metabolites given by pure MeOH extractions. While it was shown 557 that the number of lipids and derivatives were increased in the samples extracted using 558 MeOH in comparison to the other groups, the overall metabolic coverage was very similar 559 for all extraction solvents investigated. As maximal chemical coverage is largely main-560 tained, it can again be noted that metabolite class is conserved across extraction solvents. 561 As the use of pure MeOH increases overall metabolic features obtained from molecules 562 across a wide range of different chemical properties, its use can therefore be recom-563 mended as the optimal solvent for faecal extraction. This result is in agreement with a 564 recently reported study, where MeOH was chosen as the optimal solvent for extraction of 565 metabolites from human faecal samples to assess gut health [19]. Furthermore, MeOH has 566 been found to be the optimal extraction solvent in a range of metabolomics studies includ-567 ing investigation of dietary influences in faecal samples [3], serum metabolite profiling 568 [20], and Blastocystis' metabolism [21]. In comparison to one of the current most used ex-569 traction solvents, phosphate buffer saline (PBS) [22], the recognition of MeOH as an effi-570 cient organic buffer and resultant choice in a range of sample preparation methods may 571 be attributed to effective protein denaturation [23] and multi-polarity chemical capture 572 [24]. 573

Cell lysis is the process of breaking down the cell membrane to release contents con-575 tained inside the cell for molecular analysis. Bead beating, sonication, and cycles of freeze-576 thawing are common techniques used to disrupt the cell, and a sense of uncertainty re-577 sides about optimal methodological choice. Samples that underwent cell lysis using bead 578 beating contained a significantly higher number of m/z features than freeze-thawing and 579 a significantly increased number of identified metabolites than both those with sonication 580 and freeze-thawing. Moreover, cell disruption by bead beating had a significantly in-581 creased number of lipids compared to both other methods. Overall, these findings indicate 582 that bead beating was the most effective cell lysis method for extracting metabolites from 583 human faecal samples. Additional studies have found analogous findings, for example, 584 one study showed that bead beating was the best method for cell disruption and subse-585 quent extraction of both polar and non-polar compounds from platelet samples, as given 586 by optimal extraction efficiencies [25]. Bead beating has also previously been used as the 587 cell lysis method of choice in sample preparation of human feacal samples [26], as well as 588 for gastrointestinal stromal tumour [27] and characterisation of tissue samples [28]. 589

Sample-to-solvent ratio, as aforementioned, is vital not only to maximise the data 591 obtained but also to ensure sufficient sample quality for LC-MS analysis so as not to cause 592 blockage and instrument breakdown. This is particularly important for complex bioma-593 trices such as faeces, which are composed of an abundance of organic and cellular mate-594 rial. The sample-to-solvent ratio therefore must allow extraction of large metabolite num-595 bers that are compatible with LC-MS systems. Therefore, the metabolic output resulting 596 from sample-to-solvent ratios of 1:5, 1:10, and 1:20 were assessed. Different metabolite 597 quantification analyses identified a higher number of m/z features, identified metabolites, 598 and signal intensity were given by samples using a sample-solvent ratio of 1:20 compared 599 to the other tested ratios. Over 3000 m/z features were detected and putatively identified 600 using the optimal procedure with a 1:20 sample-solvent ratio, which holds great promise 601

All rights reserved. No reuse allowed without permission.

for maximising capture of biological information in future metabolomic studies. It is important to note that this work is part of an ongoing effort to document the metabolites putatively identified in faecal samples which will in future will be built upon by the creation of a standards library and the additional use of pure standards. This will help work towards reporting standards of chemical analysis [29] and increase the confidence of identification.

Finally, we demonstrated the applicability of the method on samples from patients 609 with two forms of gastrointestinal disease involving metabolic and microbial perturba-610 tion, CD and CoD [30, 31]. The developed method successfully detected and differentiated 611 metabolic patterns of each group with a wide coverage. The method demonstrates strong 612 cross-platform compatibility, with successful method application using two distinct ana-613 lytical platforms, Orbitrap 240 LC-MS (ThermoFisher Scientific) and targeted triple-quad-614 rupole (Shimadzu UK). This is valuable for future use of the method in laboratories using 615 different technologies for metabolomic analysis. 616

While contradictive reports are found regarding metabolite extraction procedures, it 618 is important to bring to light methods that are suitable in specific contexts to continue the 619 drive towards standardisation. The use of biphasic extraction protocols is common in 620 metabolomics sample preparation; however, method advancement must also reflect ame-621 nability to study design. A considerable amount of research [28, 32-34] suggests the im-622 portance of single-phase extraction procedures that can be used as a simpler, faster, and 623 scalable alternatives to some of the more-extensive approaches, giving impetus for inves-624 tigating the optimal monophasic extraction protocol for human faecal samples. Rapid and 625 easy-to-use methods can greatly simplify metabolite extraction and thereby improve 626 scalability and application in large clinical studies. In this sense, single-phase methods are 627 advantageous as the single layer can easily be removed, minimizing the risk of sample 628 loss and contamination. This is of paramount importance for large studies and those with 629 limited sample amounts. Moreover, the method developed in this study uses fewer toxic 630 chemicals and can therefore be deemed as more friendly to both the operator and envi-631 ronment. 632

In summary, untargeted and targeted LC-MS analysis of different extraction factors 634 provides an insight into the specific methods which give the strongest metabolic output. 635 Optimised sample pre-treatment and extraction methods ultimately improve protocol ef-636 ficiency while simultaneously enhancing the MS signal obtained. Each small parameter 637 change causes a small increase in the efficiency of LC-MS characteristics and so when 638 combined, the accumulated difference in the overall protocol can result in a large im-639 provement to the quality of data obtained. This is particularly important when using LC-640 MS instrumentation of high sensitivity, and in doing so, the likelihood of matrix effects is 641 also decreased. Furthermore, reproducibility of the method and the instrument are in-642 creased by documenting and working towards method standardisation. As the results 643 from this study bring together some of the parameters of faecal metabolite extraction in 644 agreement with existing studies, this supports evidence of an optimised and reproducible 645 protocol that can be applied in a vast array of research and clinical settings. Moreover, the 646 method covers a wide range of metabolites of different physiochemical properties to in-647 crease the capture of biological compounds. As an extension, employing the method to 648 patients with gastrointestinal disease expands the protocol applicability to different sam-649 ple types. This method addresses the requirement for affordable, reproducible, and envi-650 ronmentally friendly metabolite extraction protocols. Thus, the method described build 651 on the foundations of protocol standardisation, allowing improved comparisons of future 652 metabolomics studies using faecal samples. 653

5. Conclusions

654

608

617

All rights reserved. No reuse allowed without permission.

Based on a series of optimisation experiments, we describe a protocol to extract me-655 tabolites from faecal samples for metabolomic analysis using an LC-MS system. We rec-656 ommend the use of 50 mg freeze-dried faecal samples in a 1000 µL MeOH and beat-657 ing extraction, as given by a reproducible increased metabolite measurement. The opti-658 mised faecal extraction method described here can be used for metabolomics investiga-659 tions of a wide array of applications, with strong evidence for its suitability in studies of 660 gastrointestinal disease. This contributes towards standardizing a framework of sample 661 preparation, allowing easier and more accurate comparisons between studies. 662

Author Contributions: "Conceptualisation, P.E.K, G.F, Z.R, K.G. and N.J.W.R.; methodology, P.E.K, 664 H.J.N, S.M, Z.R, K.G and N.J.WR.; software, P.E.K, G.F and N.J.W.R.; validation, P.E.K, G.F and 665 N.J.W.R.; formal analysis, .E.K, H.J.N, S.M, Z.R, K.G and N.J.WR; investigation, .E.K, H.J.N, S.M, 666 and N.J.WR .; resources, R.K.R, R.H and K.G; data curation, P.E.K, G.F and N.J.W.R; writing-orig-667 inal draft preparation, .P.E.K and N.J.WR ; writing-review and editing, P.E.K, H.J.N, G.F, S.M, 668 R.K.R, R.H, Z.R, K.G and N.J.W.R; visualisation, P.E.K and N.J.W.R; supervision, N.J.W.R, Z.R and 669 K.G; project administration, N.J.W.R; funding acquisition, N.J.W.R, K.G and Z.R. All authors have 670 read and agreed to the published version of the manuscript." 671

Funding: This study was supported by Shimadzu UK and the University of Strathclyde through672joint contribution to P.E.K's studentship. The clinical studies were funded by the Glasgow Children673Hospital Charity and the Nutricia Research Foundation. ZR would like to acknowledge the EPSRC674Multiscale Metrology Suite (EP/V028960/1).675

Institutional Review Board Statement: The study was conducted in accordance with the Declara-<br/>tion of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of NHS<br/>West of Scotland Research Ethics Committee (Ref: 11/WS/0006) for the study in patients with coeliac<br/>disease and the Yorkhill Research Ethics Committee (Reb: 05/S0708/66) for the study in patients with<br/>Crohn's disease.676<br/>677678<br/>680679679

Informed Consent Statement: Informed consent was obtained from all subjects involved in the 681 study. 682

**Data Availability Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Acknowledgments:** N.J.W.R would like to acknowledge the Strathclyde Centre of Molecular Bioscience (<u>www.scmb.strath.ac.uk</u>) for access to LCMS instrumentation.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the<br/>design of the study; in the collection, analyses, or interpretation of data; in the writing of the manu-<br/>script; or in the decision to publish the results.689691

692

683

684

685 686

687

688

663

693

694

- 695
- 696 697

References

Wishart, D.S.; Guo, A; Oler, E; Wang, F; Anjum, A; Peters, H; Dizon, R; Sayeeda, Z; Tian, S; Lee, B.L; Berjanskii, M; Mah,
 R; Yamamoto, M; Jovel, J; Torres-Calzada, C; Hiebert-Giesbrecht, M; Lui, V.W; Varshavi, D; Varshavi, D; Allen, D; Arndt,
 D; Khetarpal, N; Sivakumaran, A; Harford, K; Sanford, S; Yee, K; Cao, X; Budinski, Z; Liigand, J; Zhang, L; Zheng, J; Man dal, R; Karu, N; Dambrova, M; Schiöth, HB; Greiner, R; Gautam, V. HMDB 5.0: the Human Metabolome Database for
 2022. Nucleic Acids Res. 2022. 50(D1): D622-D631. doi: 10.1093/nar/gkab1062.

All rights recomind	No rouse	allowed	1.1.1.th a	normionion
All nonis reserved	NO IEUse	allowed	WITTEN	Dennission
/ 11 119110 10001100		anonoa	with ite at	

2.	Zierer, J; Jackson, M.A; Kastenmüller, G; Mangino, M; Long, T; Telenti, A; Mohney, R.P; Small, K.S; Bell, J.T; Steves, C.J;	703
	Valdes, A.M; Spector, T.D; Menni, C. The fecal metabolome as a functional readout of the gut microbiome. Nat Genet.	704
	<b>2018</b> . 50(6):790-795. doi: 10.1038/s41588-018-0135-7.	705
3.	Erben, V; Poschet, G; Schrotz-King, P; Brenner, H. Evaluation of different stool extraction methods for metabolomics	706
	measurements in human faecal samples. BMJ NPH. 2020. 4(2): 374-384. doi: 10.1136/bmjnph-2020-000202.	707
4.	Coker, O. O; Liu, C; Wu, W. K. K; Wong, S. H; Jia, W; Sung, J. J. Y., & Yu, J. Altered gut metabolites and microbiota inter-	708
	actions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome. 2022.	709
	10(1). doi: 10.1186/s40168-021-01208-5.	710
5.	Yu, D; Du, J; Pu, X; Zheng, L; Chen, S; Wang, N; Li, J; Chen, S; Pan, S; Shen, B. The Gut Microbiome and Metabolites Are	711
	Altered and Interrelated in Patients With Rheumatoid Arthritis. Front Cell Infect Microbiol. 2022. 11: 763507. doi:	712
	10.3389/fcimb.2021.763507.	713
6.	Fang, Q; Liu, N; Zheng, B; Guo, F; Zeng, X; Huang, X; Ouyang, D. Roles of Gut Microbial Metabolites in Diabetic Kidney	714
	Disease. Front Endocrinol. 2021. 12: 636175. doi: 10.3389/fendo.2021.636175.	715
7.	Zheng, L; Wen, X. L; Duan, S. L. Role of metabolites derived from gut microbiota in inflammatory bowel disease. World J.	716
	Clin. Cases. 2022. 10(9): 2660–2677. doi: 10.12998/wjcc.v10.i9.2660.	717
8.	Di Cagno, R; Rizzello, CG; Gagliardi, F; Ricciuti, P; Ndagijimana, M; Francavilla, R; Guerzoni, ME; Crecchio, C; Gobbetti,	718
	M; De Angelis, M. Different fecal microbiotas and volatile organic compounds in treated and untreated children with	719
	celiac disease. Appl Environ Microbiol. 2009. 75(12): 3963-71. doi: 10.1128/AEM.02793-08.	720
9.	Metwaly, A.; Dunkel, A.; Waldschmitt, N.; Raj, A. C. D.; Lagkouvardos, I.; Corraliza, A. M.; Mayorgas, A.; Martinez-Me-	721
	dina, M.; Reiter, S.; Schloter, M.; Hofmann, T.; Allez, M.; Panes, J.; Salas, A.; Haller, D. Integrated microbiota and metabo-	722
	lite profiles link Crohn's disease to sulfur metabolism. Nat. Commun. 2020. 11(1): 4322. doi: 10.1038/s41467-020-17956-1.	723
10.	Heinken, A.; Hertel, J.; Thiele, I. Metabolic modelling reveals broad changes in gut microbial metabolism in inflammatory	724
	bowel disease patients with dysbiosis. npj Syst Biol Appl. 2021. 7(1):19. doi: 10.1038/s41540-021-00178-6.	725
11.	Khalkhal, E.; Rezaei-Tavirani, M.; Fathi, F.; Nobakht M Gh, BF.; Taherkhani, A.; Rostami-Nejad, M.; Asri, N.; Haidari,	726
	MH. Screening of Altered Metabolites and Metabolic Pathways in Celiac Disease Using NMR Spectroscopy. Biomed Res	727
	Int. 2021. 1798783. doi: 10.1155/2021/1798783.	728
12.	Martín-Masot, R.; Mota-Martorell, N.; Jové, M.; Maldonado, J.; Pamplona, R.; Nestares, T. Alterations in one-carbon me-	729
	tabolism in celiac disease. Nutrients. 2020. 12(12), 1–14. doi: 10.3390/nu12123723.	730
13.	Hosseinkhani, F.; Dubbelman, A. C.; Karu, N.; Harms, A. C.; Hankemeier, T. Towards standards for human fecal sample	731
	preparation in targeted and untargeted lc-hrms studies. Metabolites. 2021, 11(6). doi: 10.3390/metabo11060364.	732
14.	Moosmang, S.; Pitscheider, M.; Sturm, S.; Seger, C.; Tilg, H.; Halabalaki, M.; Stuppner, H. Metabolomic analysis—Ad-	733
	dressing NMR and LC-MS related problems in human feces sample preparation. Clinica Chimica Acta. 2019. 489, 169–176.	734
	doi: 10.1016/j.cca.2017.10.029.	735
15.	Nandania, J.; Peddinti, G.; Pessia, A., Kokkonen, M.; Velagapudi, V. Validation and automation of a high-throughput	736
	multitargeted method for semiquantification of endogenous metabolites from different biological matrices using tandem	737
	mass spectrometry. <i>Metabolites</i> . <b>2018</b> . <i>8</i> (3). doi: 10.3390/metabo8030044.	738
16.	Wu, J.; An, Y.; Yao, J.; Wang, Y.; Tang H. An optimised sample preparation method for NMR-based faecal metabonomic	739
	analysis. <i>Analyst.</i> <b>2010</b> . 135: 1023–30. doi: 10.1039/b927543f.	740
17.	Gholib, G; Heistermann, M; Agil, M; Supriatna, I; Purwantara, B; Nugraha, T.P; Engelhardt, A. Comparison of fecal	741
	preservation and extraction methods for steroid hormone metabolite analysis in wild crested macaques. Primates. 2018.	742
	59(3):281-292. doi: 10.1007/s10329-018-0653-z.	743
18.	Zhao, X.; Zhang, Z.; Hu, B.; Huang, W.; Yuan, C.; Zou, L. Response of gut microbiota to metabolite changes induced by	744
	endurance exercise. Front. Micro. 2018. 9:765. doi: 10.3389/fmicb.2018.00765.	745

19.	de Zawadzki, A; Thiele, M; Suvitaival, T; Wretlind, A; Kim, M; Ali, M; Bjerre, A. F; Stahr, K; Mattila, I; Hansen, T; Krag,	746
	A; Legido-Quigley, C. High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health. Metabolites.	747
	<b>2022</b> . <i>12</i> (3). doi: 10.3390/metabo12030211.	748
20.	Want, E.J; O'Maille, G; Smith, C.A; Brandon, T.R; Uritboonthai, W; Qin, C; Trauger, S.A; Siuzdak, G. Solvent-dependent	749
	metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem. 2006.	750
	78(3):743-52. doi: 10.1021/ac051312t.	751
21.	Newton, J. M; Betts, E. L; Yiangou, L; Roldan, J. O; Tsaousis, A. D; Thompson, G. S. Establishing a metabolite extraction	752
	method to study the metabolome of blastocystis using nmr. <i>Molecules</i> . 2011. 26(11). doi: 10.3390/molecules26113285.	753
22.	Deda, O; Gika, H. G; Wilson, I. D; Theodoridis, G. A. An overview of fecal sample preparation for global metabolic profil-	754
	ing. J. Pharm. Biomedical. 2015. 113: 137–150. doi: 10.1016/j.jpba.2015.02.006.	755
23.	Zeng, M; Cao, H. Fast quantification of short chain fatty acids and ketone bodies by liquid chromatography-tandem	756
	massspectrometry after facile derivatization coupled with liquid-liquid extraction.J. Chromatogr. B Anal. Technol. Bio-	757
	med. Life Sci. 2018. 1083, 137–14. doi: 10.1016/j.jchromb.2018.02.040.	758
24.	Vuckovic, D. Current trends and challenges in sample preparation for global metabolomics using liquid chromatog-	759
	raphy-massspectrometry. Anal Bioanal Chem. 2012. 403, 1523–1548. doi: 10.1007/s00216-012-6039-y.	760
25.	Fu, X; Calderón, C; Harm, T; Gawaz, M; Lämmerhofer, M. Advanced unified monophasic lipid extraction protocol with	761
	wide coverage on the polarity scale optimized for large-scale untargeted clinical lipidomics analysis of platelets. Analytica	762
	Chimica Acta. 2022. 1221, 340155. doi:10.1016/j.aca.2022.340155.	763
26.	Cheng, K; Brunius, C; Fristedt, R; Landberg, R. An LC-QToF MS based method for untargeted metabolomics of human	764
	fecal samples. Metabolomics. 2020. 16(4). doi: 10.1007/s11306-020-01669-z.	765
27.	Macioszek, S; Dudzik, D; Jacyna, J; Wozniak, A; Schöffski, P; Markuszewski, M. J. A robust method for sample prepara-	766
	tion of gastrointestinal stromal tumour for LC/MS untargeted metabolomics. Metabolites. 2021. 11(8). doi:	767
	10.3390/metabo11080554.	768
28.	Southam, A. D; Pursell, H; Frigerio, G; Jankevics, A; Weber, R. J. M; Dunn, W. B. Characterization of Monophasic Solvent-	769
	Based Tissue Extractions for the Detection of Polar Metabolites and Lipids Applying Ultrahigh-Performance Liquid Chro-	770
	matography-Mass Spectrometry Clinical Metabolic Phenotyping Assays. J. Proteome Res. 2021. 20(1), 831-840. doi:	771
	10.1021/acs.jproteome.0c00660.	772
29.	Sumner, L.W; Amberg. A; Barrett, D; Beale, M.H; Beger, R; Daykin, C.A; Fan, T.W; Fiehn, O; Goodacre, R; Griffin, J.L;	773
	Hankemeier, T; Hardy, N; Harnly, J; Higashi, R; Kopka, J; Lane, A.N; Lindon, J.C; Marriott, P; Nicholls, A.W; Reily, M.D;	774
	Thaden, J.J; Viant, M.R. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working	775
	Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 2007. 3(3):211-221. doi: 10.1007/s11306-007-0082-	776
	2.	777
30.	Zafeiropoulou, K; Nichols, B; Mackinder, M; Biskou, O; Rizou, E; Karanikolou, A; Clark, C; Buchanan, E; Cardigan, T;	778
	Duncan, H; Wands, D; Russell, J; Hansen, R; Russell, R.K; McGrogan, P; Edwards, C.A; Ijaz, U.Z; Gerasimidis K. Altera-	779
	tions in Intestinal Microbiota of Children With Celiac Disease at the Time of Diagnosis and on a Gluten-free Diet. Gastro-	780
	enterology. 2020. 159(6):2039-2051.e20. doi: 10.1053/j.gastro.2020.08.007.	781
31.	Quince, C; Ijaz, U.Z; Loman, N; Eren, A.M; Saulnier, D; Russell, J; Haig, S.J; Calus, S.T; Quick. J; Barclay, A; Bertz, M;	782
	Blaut, M; Hansen, R; McGrogan, P; Russell, R.K; Edwards, C.A; Gerasimidis K. Extensive Modulation of the Fecal Meta-	783
	genome in Children With Crohn's Disease During Exclusive Enteral Nutrition. Am J Gastroenterol. 2015. 110(12):1718-29.	784
	doi: 10.1038/ajg.2015.357.	785
32.	Medina, J; van der Velpen, V; Teav, T; Guitton, Y; Gallart-Ayala, H; Ivanisevic, J. Single-step extraction coupled with tar-	786
	geted hilic-ms/ms approach for comprehensive analysis of human plasma lipidome and polar metabolome. <i>Metabolites</i> .	787

33.	Alshehry, Z. H; Barlow, C. K; Weir, J. M; Zhou, Y; McConville, M. J; Meikle, P. J. An efficient single phase method for the	789
	extraction of plasma lipids. Metabolites. 2015. 5(2), 389–403. doi: 10.3390/metabo5020389.	790
34.	Peterson, A.L; Walker, A.K; Sloan E.K; Creek D.J. Optimized Method for Untargeted Metabolomics Analysis of MDA-	791
	MB-231 Breast Cancer Cells. Metabolites. 2016. 6(4):30. doi: 10.3390/metabo6040030.	792